Additional file 5: Figure S2 Assessment of the prognostic risk signature in GSE136337. A The distributions of risk score, survival status and expression profile of signature genes between the risk groups. B K-M survival analysis between the high- and low-risk groups. C ROC curve at 1-, 3- and 5-years of prognostic value of the prognostic inde
Figure S5. KaplanâMeier survival analysis based on risk score model system (a) and Luminal subtype...
List of mRNAs co-expressed with at least one of the four prognostic lncRNAs. (XLS 131Â kb
Background. An increasing number of studies have indicated that the abnormal expression of certain l...
Additional file 4: Figure S1 Assessment of the prognostic risk signature in TCGA. A The distribution...
Additional file 6: Figure S3 Assessment of the prognostic risk signature. A K-M survival analysis in...
Additional file 2: Table S2 Differential IC50s observed for 168 drugs in two group
Abstract Background About 10% of hematologic malignancies are multiple myeloma (MM), an untreatable ...
Additional file 7: Figure S4 Effects of Nelarabine, Carmustine and Temozolomide on apoptotic death, ...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Additional file 5. Distribution of expression of signature genes in low- and high-risk patients. (A)...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
List of enriched GO terms and KEGG pathways of mRNAs co-expressed with prognostic lncRNAs. (XLS 72Â ...
Figure S5. KaplanâMeier survival analysis based on risk score model system (a) and Luminal subtype...
List of mRNAs co-expressed with at least one of the four prognostic lncRNAs. (XLS 131Â kb
Background. An increasing number of studies have indicated that the abnormal expression of certain l...
Additional file 4: Figure S1 Assessment of the prognostic risk signature in TCGA. A The distribution...
Additional file 6: Figure S3 Assessment of the prognostic risk signature. A K-M survival analysis in...
Additional file 2: Table S2 Differential IC50s observed for 168 drugs in two group
Abstract Background About 10% of hematologic malignancies are multiple myeloma (MM), an untreatable ...
Additional file 7: Figure S4 Effects of Nelarabine, Carmustine and Temozolomide on apoptotic death, ...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Additional file 5. Distribution of expression of signature genes in low- and high-risk patients. (A)...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
Background: Multiple myeloma (MM) is one of the most common types of hematological malignance, and t...
List of enriched GO terms and KEGG pathways of mRNAs co-expressed with prognostic lncRNAs. (XLS 72Â ...
Figure S5. KaplanâMeier survival analysis based on risk score model system (a) and Luminal subtype...
List of mRNAs co-expressed with at least one of the four prognostic lncRNAs. (XLS 131Â kb
Background. An increasing number of studies have indicated that the abnormal expression of certain l...